Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone

KJ Fehske, U Schlafer, U Wollert and WE Muller

This paper reports a variety of experimental observations which strongly support the assumption that the warfarin binding site, or site I of human serum albumin, is better described as the warfarin- azapropazone binding area, consisting of the overlapping binding sites for warfarin and azapropazone. In general, drugs interacting with one of the two sites will also displace drugs bound to the other site, although their displacing potencies for both sites may vary considerably. This is most pronounced in the case of glibenclamide, which strongly inhibits the binding of drugs to the azapropazone site with only minor effects on drugs bound to the warfarin site. The lone tryptophan residue of human serum albumin, previously shown to be part of the warfarin binding site, is obviously located in the not- overlapping part of the warfarin site, so that its modification affects only the binding of drugs to the warfarin and not to the azapropazone site of this large binding area. The observation of different but overlapping binding sites might explain the fact that the albumin binding of drugs which seem to be bound to similar sites because of their mutual displacement can be affected differently during several disease states.

Volume 21, Issue 2, pp. 387-393, 03/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				T. Ito, M. Takahashi, K. Sudo, and Y. Sugiyama Marked Strain Differences in the Pharmacokinetics of an {alpha}4beta1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 124 - 132. [Abstract] [Full Text] [PDF]

				H. Mandula, J. M. R. Parepally, R. Feng, and Q. R. Smith Role of Site-Specific Binding to Plasma Albumin in Drug Availability to Brain J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 667 - 675. [Abstract] [Full Text] [PDF]

				S.-F. Ma, M. Anraku, Y. Iwao, K. Yamasaki, U. Kragh-Hansen, N. Yamaotsu, S. Hirono, T. Ikeda, and M. Otagiri HYDROLYSIS OF ANGIOTENSIN II RECEPTOR BLOCKER PRODRUG OLMESARTAN MEDOXOMIL BY HUMAN SERUM ALBUMIN AND IDENTIFICATION OF ITS CATALYTIC ACTIVE SITES Drug Metab. Dispos., December 1, 2005; 33(12): 1911 - 1919. [Abstract] [Full Text] [PDF]

				S.A. David, P. Balaram, and V.I. Mathan Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin carrier function for albumin Innate Immunity, April 1, 1995; 2(2): 99 - 106. [Abstract] [PDF]

				I. Petitpas, A. A. Bhattacharya, S. Twine, M. East, and S. Curry Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin. ANATOMY OF DRUG SITE I J. Biol. Chem., June 15, 2001; 276(25): 22804 - 22809. [Abstract] [Full Text] [PDF]